Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Thomas Richard Kassberg Sells 6,028 Shares of Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Thomas Richard Kassberg sold 6,028 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $253,778.80. Following the transaction, the executive vice president now directly owns 265,238 shares in the company, valued at approximately $11,166,519.80. This represents a 2.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Ultragenyx Pharmaceutical Stock Down 0.4 %

Shares of Ultragenyx Pharmaceutical stock opened at $41.10 on Wednesday. The business has a 50 day moving average of $42.86 and a 200 day moving average of $49.03. Ultragenyx Pharmaceutical Inc. has a 52 week low of $37.02 and a 52 week high of $60.37. The company has a market cap of $3.80 billion, a PE ratio of -6.48 and a beta of 0.60.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.32) by ($0.07). The company had revenue of $164.88 million during the quarter, compared to the consensus estimate of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. On average, research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have commented on RARE shares. Canaccord Genuity Group lifted their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a research note on Tuesday, February 18th. Wedbush reiterated a “neutral” rating and issued a $48.00 target price (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. Wells Fargo & Company upped their price target on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a research report on Friday, December 20th. Royal Bank of Canada reiterated an “outperform” rating and issued a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Finally, Piper Sandler raised their price target on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, January 13th. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $93.50.

Institutional Trading of Ultragenyx Pharmaceutical

Several institutional investors and hedge funds have recently bought and sold shares of RARE. International Assets Investment Management LLC raised its position in shares of Ultragenyx Pharmaceutical by 29,580.0% in the 3rd quarter. International Assets Investment Management LLC now owns 10,388 shares of the biopharmaceutical company’s stock worth $577,000 after acquiring an additional 10,353 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Ultragenyx Pharmaceutical by 34.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,333 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 851 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Ultragenyx Pharmaceutical by 195.6% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 21,753 shares of the biopharmaceutical company’s stock valued at $1,208,000 after buying an additional 14,394 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of Ultragenyx Pharmaceutical by 740.0% during the 3rd quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company’s stock valued at $4,802,000 after buying an additional 76,150 shares in the last quarter. Finally, Capital Performance Advisors LLP purchased a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth about $107,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.